It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
Healthy arm - age and gender matched to patient arm
Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
Study partner available for study visits
Prior stroke or other uncontrolled serious neurological or medical illness
Contra-indication or inability to tolerate MRI scan
Use of serotonergic medications in the last 6 weeks
Incapable of providing independent consent.
Vanderbilt University Medical Center
Lead sponsor
ACADIA Pharmaceuticals Inc.
Collaborator